What Redox Doubters Missed
If Redox was on your watchlist rather than in your portfolio, the result may feel like a missed shot. Holding Redox over the past year would have returned 24.8%, including dividends. That outcome naturally raises a question. Back on 30 October 2025, what clues in the specialty chemicals thesis and the push into higher margin products could have helped you judge whether growing demand would actually flow through to stronger profitability?
A Narrative on Simply Wall St is one investor's written case for a company, with its growth, margin and multiple assumptions spelled out. Those assumptions imply an estimated Fair Value.
The easy part of this move is behind Redox. Zero in on 1 high quality undervalued stocks for companies trading below our estimates.
The Two Redox Stories Investors Had To Weigh
The shares cost A$2.85 at the start, and Redox sat between two very different stories about where the chemicals distributor might be heading.
On the optimistic side, the growth case put Fair Value at A$3.56, or 25% above the start price. That view leaned on revenue rising 9.8% a year and profit margins edging to 6.7%, helped by a broader specialty portfolio and heavier investment in its ERP and logistics systems.
The cautious camp saw Fair Value closer to A$2.68, or 6% below the start price. This more sceptical view focused on rising regulatory costs, pressure on margins from lower margin segments, and the risk that digital commerce and direct sourcing could chip away at distributor economics.
What The Results Put To The Redox Thesis
Redox reported total revenue of A$611.95m in H2 2025 and A$656.61m in H2 2026, while net income rose from A$36.89m to A$48.13m and net margin widened from 6.0% to 7.3%. The launch of RDX-Flex, a crop biostimulant planned for the 2027 season, leaned toward the optimistic case on higher margin specialty products. Overall, the evidence cut both ways but tilted supportive.
The decision back in October 2025 really hinged on whether specialty products and systems spending would show up in margins. For a different stock, it may be useful to test that same claim by tracking reported net margin and the mix of higher value products rather than only watching revenue or headlines about expansion.
What You Are Paying For In Redox Today
Redox now trades at A$3.47. The selected Narrative places its Fair Value above that figure, framing today’s quote as cautious relative to the firm’s higher margin push and use of its Redebiz platform.
On this view, the share price still does not fully credit Redox converting pricing power, RDX Flex and bolt on deals into sustained, high quality earnings.
"The main thing that has to go right is that Redox continues to use its Redebiz platform, broad supplier and customer base, and strong balance sheet to convert supply chain volatility, tariffs and planned bolt on acquisitions into profitable growth rather than sustained cost pressure."
That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for
Redox And What Keeps Data On
Once you understand Redox, it is natural to ask what sits one step away. Where does all that chemistry powered demand actually live?
Those materials often end up supporting factories, warehouses and digital infrastructure. The digital side quietly leans on a different kind of backbone.
High intensity computing loads throw off huge amounts of heat. One specialist player focuses on power systems and cooling gear that keep facilities running.
Its hardware and services help data centres keep critical equipment online. As AI workloads spread, that behind the scenes role could matter more.
That argument has a Narrative and a number behind it. → See the company one Narrative values 66% above its price
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com